key: cord-0886537-gxvaric3
authors: Lemos, Anna Cristina Bertoldi; do Espírito Santo, Douglas Alexandre; Salvetti, Maísa Cabetti; Gilio, Renato Noffs; Agra, Lucas Barbosa; Pazin-Filho, Antonio; Miranda, Carlos Henrique
title: Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
date: 2020-09-21
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.09.026
sha: b9c8808d66f6b5bae5e2f111e6d8d1a79916d77a
doc_id: 886537
cord_uid: gxvaric3

INTRODUCTION: Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state. Several autopsy studies have found microthrombi in pulmonary circulation. METHODS: In this randomized, open-label, phase II study, we randomized COVID-19 patients requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard anticoagulant thromboprophylaxis. We evaluated the gas exchange over time through the ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at baseline, 7, and 14 days after randomization, the time until successful liberation from mechanical ventilation, and the ventilator-free days. RESULTS: Ten patients were assigned to the therapeutic enoxaparin and ten patients to prophylactic anticoagulation. There was a statistically significant increase in the PaO2/FiO2 ratio over time in the therapeutic group (163 [95% confidence interval – CI 133–193] at baseline, 209 [95% CI 171–247] after 7 days, and 261 [95% CI 230–293] after 14 days), p = 0.0004. In contrast, we did not observe this improvement over time in the prophylactic group (184 [95% CI 146–222] at baseline, 168 [95% CI 142–195] after 7 days, and 195 [95% CI 128–262] after 14 days), p = 0.487. Patients of the therapeutic group had a higher ratio of successful liberation from mechanical ventilation (hazard ratio: 4.0 [95% CI 1.035–15.053]), p = 0.031 and more ventilator-free days (15 days [interquartile range IQR 6–16] versus 0 days [IQR 0–11]), p = 0.028 when compared to the prophylactic group. CONCLUSION: Therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID–19. TRIAL REGISTRATION: REBEC RBR-949z6v.

an acute respiratory failure with extreme hypoxemia, which ultimately requires mechanical ventilation [1] . Recent clinical investigations found a high incidence of thrombotic complications in these patients, even with the standard anticoagulant thromboprophylaxis [2, 3] . In addition to diffuse alveolar damage, several autopsy studies have demonstrated microthrombi in pulmonary circulation [4] [5] [6] [7] [8] . This microvascular thrombosis may contribute to impaired gas exchange in these patients.

Some observational studies have shown anticoagulation benefits with reduced mortality, mainly in patients requiring mechanical ventilation [9, 10] . However, considerable levels of uncertainty remain about this therapy.

Our objective was to evaluate whether therapeutic anticoagulation could improve gas exchange compared to the standard anticoagulant thromboprophylaxis, reducing the need to maintain mechanical ventilation in severe COVID-19 patients.

In this randomized, controlled, open-label, single-center, phase II study, we randomized patients with respiratory failure requiring mechanical ventilation and laboratorially confirmed SARS-CoV-2 infection to receive either therapeutic anticoagulation with enoxaparin or the standard anticoagulant thromboprophylaxis.

The third arm of this study with therapeutic intravenous unfractionated heparin (UFH) was abandoned due to difficulties in adjusting the activated partial thromboplastin time (aPTT) during the pandemic. The study was approved by the Research Ethics J o u r n a l P r e -p r o o f Journal Pre-proof Committee of our institution and followed the Declaration of Helsinki. The subjects or their relatives gave their written informed consent before enrollment in this study.

The inclusion criteria were patients with age over 18 years-old, SARS-CoV-2 infection confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR), presence of acute respiratory distress syndrome (ARDS) according to the Berlin definition [11] , severe clinical presentation with respiratory failure requiring mechanical ventilation, D-dimer levels greater than 1000 μg/L; prothrombin time/international normalized ratio (INR)<1.5; activated partial thromboplastin time (aPTT)/ratio<1.5, and platelet count greater than 100,000/mm 3 . The exclusion criteria were patients with age greater than 85 years-old, creatinine clearance (CrCl)<10 ml/min, severe circulatory shock with a dose of norepinephrine higher than 1.0 μg/kg/min, chronic renal failure in renal replacement therapy, Child B and C chronic liver disease, advanced diseases, such as active cancer, heart failure with functional class III and IV (New York Heart Failure Association), chronic obstructive pulmonary disease using home oxygen, advanced dementia, significant disability from stroke or severe head injury, cardiorespiratory arrest, pregnant women, recent major surgery or severe trauma in the last 3 weeks, recent stroke in the last 3 months, active bleeding, blood dyscrasia such as hemophilia, Von Willebrand factor deficiency, participation in another clinical investigation, indication for therapeutic anticoagulation due to pulmonary embolism, and acute coronary syndrome.

For all patients, baseline characteristics and laboratory tests were retrieved from the medical records using a standardized data collection.

J o u r n a l P r e -p r o o f

We used blocked randomization, and the participants were randomized in a 1:1 ratio within two blocks of ten patients each. The patients were assigned to each treatment by drawing the sequential numbering of opaque envelopes containing the treatment allocation. The therapeutic enoxaparin group was allocated to receive subcutaneous (SC) enoxaparin with the dose according to age and adjusted daily by the creatinine clearance CrCl<10 ml/min: similar to younger patients. Enoxaparin has a high degree of renal excretion and renal function can modify abruptly in critically ill patients. This drug accumulation, mainly in renal impairment and elderly patients, increases the bleeding risk. Because of this, we decided to use a more multitiered enoxaparin dose adjustment in these patients [12, 13] . Therapeutic enoxaparin should be maintained for at least 96 hours; however, we recommend maintaining it for up to 14 days. and 40 mg BID (if weight >120 Kg) according to the doctor's judgment.

The primary outcome was the variation in gas exchange over time evaluated through the ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at baseline, 7, and 14 days after randomization. This ratio was blindly calculated using the result of the arterial blood gas (ABG) analysis collected routinely around 6:00 am.

The secondary outcomes were the time until successful liberation from mechanical ventilation, the ventilator-free days (during the 28 days after inclusion in the study; numbers of days without mechanical ventilation), the variation in D-dimer levels collected at baseline during inclusion in the study and repeated 72-96 h later, allcause 28-day mortality, in-hospital mortality, and the intensive care unit (ICU)-free days at 28 days.

To determine the successful liberation from mechanical ventilation, we considered the maintenance of spontaneous ventilation without the need for invasive mechanical ventilation support for a minimum of 72 h. All patients received the lung-protective ventilation strategy with low tidal volume. Each unit used its ventilator liberation protocol. The patients underwent prone positioning of at least 16 hours if PaO2/FiO2 ratio<150 mmHg. Other ventilator adjuncts to improve oxygenation in the setting of severe ARDS, such as inhaled nitric oxide and extracorporeal membrane oxygenation, were not available in our service.

The D-dimer measurement was performed through the automated assay VIDAS® Ddimer Exclusion II TM (bioMérieux SA, Lyon, France) with a cutoff of 500 μg/L.

The safety outcome analyzed was the occurrence of bleeding using the Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria, which classified the bleeding in major, minor and requiring medical attention [14] .

We used the Shapiro-Wilk test to evaluate the distribution of the continuous variables.

We expressed the continuous variables with normal distribution as mean ± standard deviation or mean and its respective 95% confidence interval (95% CI), and other variables were expressed as the median and interquartile range (IQR). We used paired and unpaired t-test to assess the difference between two continuous variables with a normal distribution. The Mann-Whitney test was used to compare two continuous variables without normal distribution. We expressed categorical variables as frequency or percentage. We used Fisher's exact test to compare two categorical variables and the paired repeated measures one-way ANOVA test followed by Tukey's multiple comparison test to compare the PaO2/FiO2 ratio at baseline, 7, and 14 days. We constructed the Kaplan-Meier curves for survival analysis and compared them using the Cox regression-based test for equality of survival curves.

We defined the sample size in 10 patients per group, considering a paired sample, a significance level of 5%, a power of 85%, and an improvement in the PaO2/FiO2 ratio from 150±50 (baseline) to 200±50 (D14) with the therapeutic enoxaparin [15] .

A two-tailed p-value less than or equal to 0.05 was considered statistically significant.

Statistical analysis and graphs were performed using the GraphPad Prism software Table 2 . Only one patient of the prophylactic anticoagulation group died before the 14th-day. We considered the last PaO2/FiO2 ratio registered at the 12th-day after randomization as the surrogate of this patient's 14th-day ratio.

The patients in the therapeutic enoxaparin group showed a higher ratio of successful We did not observe differences in the all-cause 28-day mortality rate between the therapeutic enoxaparin group 1/10 (10%) and prophylactic anticoagulation group 3/10 (30%), p=0.264, and in-hospital mortality rate 2/10 (20%) versus 5/10 (50%), p=0.160, respectively. We also did not observe any statistically significant difference in the ICU-free days (12 days [ in the therapeutic enoxaparin group vs. 0 days [IQR 0-10] in the prophylactic anticoagulation group), p=0.067. Table 2 The median of the therapeutic enoxaparin treatment duration was 14 days, ranging from 9 to 14 days. Transposition to intravenous unfractionated heparin (UFH) was unnecessary in any patient in the therapeutic enoxaparin group due to worsening renal function during the 14 days after randomization.

We did not actively investigate the occurrence of thrombotic events in these patients. J o u r n a l P r e -p r o o f As for the safety outcomes, we did not register any major bleeding in either group.

Two patients (20%) in the therapeutic enoxaparin group experienced minor bleeding (one hematuria and one femoral arterial catheter bleeding). We observed bleeding requiring medical attention in four patients (40%) of the therapeutic enoxaparin group and two patients (20%) of the prophylactic anticoagulation group; these cases were associated to a significant drop in hemoglobin levels (>5g/dl) without any clinically overt sign of hemorrhage. Hemoglobin levels dropped in both groups (4 g/dl [95% CI [3] [4] [5] [6] in the therapeutic enoxaparin group and 3g/dl [95% CI [1] [2] [3] [4] in the prophylactic anticoagulation group), p=0.063. The deaths of the two patients in the therapeutic enoxaparin group were secondary to healthcare-associated infection. Table 2 Discussion In this randomized clinical trial, therapeutic enoxaparin resulted in improved gas exchange over time, decreased D-dimer levels, and a higher ratio of successful liberation from mechanical ventilation after respiratory failure in severe COVID-19

patients.

Several studies have performed autopsies on patients who died from severe COVID-19 and found microthrombi in pulmonary circulation in most of them [4] [5] [6] [7] [8] . In one of these investigations, small thrombi in pulmonary circulation were nine times more prevalent in patients with COVID-19 compared to patients who died of influenza (p <0.001) [5] . Additionally, new vessel growth was 2.7 times higher in COVID-19 than in influenza (p<0.001) [5] . In addition to the diffuse alveolar damage, which is the hallmark of this disease, microvascular thrombosis in pulmonary circulation could compromise gas exchange, contributing to the significant hypoxemia observed in these patients. The principal hypothesis investigated in this study was whether J o u r n a l P r e -p r o o f therapeutic enoxaparin could improve these microvessels' patency, leading to improved blood oxygenation.

Our investigation showed significant improvement in the PaO2/FiO2 ratio overtime in the therapeutic enoxaparin group. On the other hand, we did not observe a significant improvement in the prophylactic anticoagulation group. Moreover, the frequency of prone positioning was similar in both groups, since this intervention showed to be effective in ameliorating blood oxygenation in acute respiratory failure due to COVID-19 [16] . Lu et al. [17] demonstrated that the oxygen saturation to the fraction of inspired oxygen (SpO2/FiO2) ratio was an important prognostic marker for critically ill COVID-19 patients, with a unit decrease in the marker corresponding to Despite evidence about coagulation activation and impaired fibrinolysis leading to fibrin deposition in the alveolar compartment in non-COVID-19 ARDS patients [18] , J o u r n a l P r e -p r o o f data about therapeutic anticoagulation's efficacy and safety is very limited in these patients [19] . Some recent investigations showed that low molecular weight heparin (LMWH) could reduce acute lung injury (ALI) in experimental models [20, 21] [15] . However, these individual trials' methodological quality was relatively low, and they were available only in Chinese databases.

D-dimer levels also appear to be a predictor of death in COVID-19 patients. Zhou et al. [22] (n=191) reported a significantly higher D-dimer of around 9-fold in nonsurvivors than survivors with severe COVID-19 (81% vs. 24%, p<0.001). Tang et al. [24] showed that D-dimer levels decreased in patients with good clinical prognosis.

COVID-19 is associated with a high prevalence of thrombotic events in both territories (macro and microvascular) [2, 5] . The mechanism responsible for this coagulopathy in COVID-19 has not been fully elucidated; however, it seems that the dysregulation of the immune response triggered by pro-inflammatory cytokines, lymphocyte cell-death, hypoxia, and endothelial damage are involved [25] . Recently, J o u r n a l P r e -p r o o f Journal Pre-proof Khider et al. [26] showed that curative anticoagulation could prevent COVID-19associated coagulopathy and endothelial lesion.

In our investigation, the therapeutic enoxaparin was prescribed for a median of 14 days. We considered this extended time because it is necessary to solve the inflammatory process before suspending the anticoagulant therapy.

Despite the COVID-19-associated coagulopathy, bleeding tendency is uncommon in this disease [25] . In comparison with bacterial-sepsis induced coagulopathy, the prolongation of prothrombin time and activated partial thromboplastin time is less frequent, and thrombocytopenia is relatively uncommon in COVID-19 [25] . The incidence of clinically evident bleeding was low in both groups, including the group with therapeutic enoxaparin. Paranjpe et al. [10] reported 3.0% of bleeding events among those receiving systemic anticoagulation compared to 1.9% among those who did not receive this treatment (p=0.2). In the investigation of Al-Samkari et al. [27] , the overall and major bleeding risks were 4.8% and 2.3%, respectively, with the most varied anticoagulation protocols in COVID-19 patients. We observed a drop in hemoglobin levels in both groups without any clinical evidence of bleeding in most patients. The inflammatory status might explain this anemia because the cytokines reduce erythropoietin levels, affect iron homeostasis by multiple mechanisms, directly inhibit erythroid cell differentiation and proliferation, and reduces red blood cell survival [28] . As a result, we considered that an isolated drop in hemoglobin levels without any clinical evidence of bleeding is not an indication to suspend therapeutic enoxaparin in these severe patients.

The main limitation of our investigation is that this single center study with a small sample size did not have sufficient power to assess a difference in mortality between the two groups. The PaO2/FiO2 ratio assessment has limitations in quantifying J o u r n a l P r e -p r o o f pulmonary dysfunction improvement; however, the increase in the PaO2/FiO2 ratio in the therapeutic enoxaparin group in our investigation was accompanied by a higher ratio of liberation from mechanical ventilation and higher ventilator-free days. The incidence of bleeding may be higher in patients older than those included in this study. Moreover, critically ill COVID-19 patients could have the documentation of clinically overt bleeding impaired due to difficulties in performing imaging tests.

Despite this, five out of six patients with hemoglobin drop higher than 5g/dl recovered from the disease and received hospital discharge without any evidence of 

Severe Covid-19

Thrombosis risk associated with COVID-19 infection. A scoping review

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Acute respiratory distress syndrome: the Berlin Definition

Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome

Dosing of Enoxaparin in Renal Impairment

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

Low-molecular-weight heparin treatment for acute lung injury/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials

Feasibility and physiological effects of prone positioning in non-intubated to COVID-19 (PRON-COVID): a prospective cohort study

Continuously available ratio of SpO2/FiO2 serves as a noninvasive prognostic marker for intensive care patients with COVID-19

Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome

Anticoagulant therapy in acute respiratory distress syndrome

Low Molecular Weight Heparin Nebulization Attenuates Acute Lung Injury

Low-Molecular-Weight Heparin Reduces Ventilation-Induced Lung Injury through

Hypoxia Inducible Factor-1alpha in a Murine Endotoxemia Model

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

Coagulopathy in COVID-19

Curative anticoagulation prevents endothelial lesion in COVID-19 patients

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection